Compare organizations

The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof, patient-oriented and leading life sciences and biotechnology sector in the EU. New biotechnology-derived vaccines and treatments have helped to tackle numerous life-threatening illnesses. Targeted cell and gene therapies and new mRNA platforms are paving the way for future treatments.

United European Gastroenterology (UEG) is the leading non-profit organisation for excellence in digestive health in Europe and beyond. We promote science, research, education, quality of care and advocate to prevent and reduce health inequalities across Europe to achieve optimal patient care. We unite 17 Specialist Member Societies and 49 National Member Societies.

In the last 20 years, biotech transformed the pharmaceutical industry and enabled the development of breakthrough therapies that are live-saving or significantly improving quality of life of patients and their families. The development of biotech in Europe also continues to positively contribute to the regions economic well-being.

United European Gastroenterology (UEG) is a professional non-profit organization combining all the leading European medical specialists and national societies focusing on digestive health. Together, we act as the united and trusted voice of European Gastroenterology, promoting science, research, education, quality of care. We aim at reducing health inequalities across Europe.

EuropaBio welcomes the EC's plan to begin a discussion with stakeholders to develop the EHDS. Science is evolving fast and digital tools are accelerating our ability to conduct research. For the biotechnology industry, it is imperative quality data sets are collected and analysed, while protecting privacy and maintaining trust in how the data are used.

UEG Response to the EU Proposal for a Regulation on Blood, tissues and cells for medical treatments & therapies United European Gastroenterology (UEG) is a professional non-profit organization combining all the leading European medical specialists and national societies focusing on digestive health.

EuropaBio welcomes the adoption of the proposal for a Regulation on SoHO revising the EU’s Blood, Tissues, and Cells (BTC) legislation. The EU needs a predictable, future-proof, and robust SoHO framework to ensure the uptake of transformative advanced therapies which hold great potential for both the health and wellbeing of patients and the sustainability of healthcare systems.